FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

AJANTPHARM

1,576.3
+18.5 (1.19%)
Updated 01:55 04/12 IST

AJANTPHARM Buy or Sell - FrontPage Forums

3 Users have submitted 3 trade ideas of Rs. 116,437.4 for AJANTPHARM
Disclaimer
100% Bullish
0% Bearish

AJANTPHARM Buy or Sell - Brokerage Reports

No. of reports in last year
2
No. of analysts
1
Average Consensus Forecast
1545
Consensus Potential
-1.34%
See AJANTPHARM Share Price Targets >>

AJANTPHARM Ratings

Long term AJANTPHARM rating by FrontPage users
3/5 (1 Ratings)
Find answers to all your questions on live AJANTPHARM message board: Is AJANTPHARM buy or sell? Should I buy AJANTPHARM shares? Why are AJANTPHARM shares falling? Should I invest in AJANTPHARM stock?

  1. Home
  2. AJANTPHARM Forum

AJANTPHARM Share Price Discussion


Ajanta Pharma has received the US Food and Drug
Administration's approval for chlorthalidone tablet in 25 mg and 50
mg strengths
Like
Reply

Tata Coffee: F Born AG sold 22,21,734 shares of Tata Coffee at Rs
105.16 per share. It held 1 .92 per cent stake in the company at the
end of last quarter
Like
Reply

Tata Group likely is in advanced talks to buy 80% stake in
BigBasket for an estimated $1 .3 billion
Like
Reply
N
Reputation: 8,253 • Dec 2 9:46 AM
39% of debt maturing in 2022 pertains to speculative-grade issuers: Moody’s
Many companies that are issuing high yield bonds may continue to face significant financing risks even going ahead as Indian economy grapples with Covid pandemic induced problems.
The Economic Times
Like
Reply

BULLION BE-ALERT TILL EVEING ONLY UP THEN DUE FOR CORRECTION. IMP US DATA TONIGHT

Like
Reply

Rolls-Royce and Infosys announce strategic partnership for
Aerospace Engineering in India
Like
Reply
A
Reputation: 2,626 • Dec 2 9:42 AM

In March, many felt that the Market can only go Down.

In December, many feel that the Market can only go Up.

Like
Reply

BTST: BUY USDINR ABV 73.98

Like
Reply

VEDL - 1718934
SC refuses Vedanta's interim plea to reopen Sterlite Copper smelting plant
Sterlite Copper smelter has been shut since May 2018 on orders of the Tamil Nadu government after mounting protests over the unit’s alleged environmental pollution boiled over into a confrontation betwe...
Read more...
1
Reply
N
Reputation: 8,253 • Dec 2 9:41 AM
About 39% of $16 billion debt maturing in 2022 pertains to speculative grade issuers: Moody’s research
Many companies that are issuing high yield bonds may continue to face significant financing risks even going ahead as Indian economy grapples with Covid pandemic induced problems.
The Economic Times
Like
Reply

Type
Sell
Instrument
CRUDEOIL 18DEC20 FUT
Entry Price
₹3,287
Price@Trade
₹3,286
Target Price
₹3,266
Stop Price
₹3,300
Valid Till
Dec 2, 2020 11:20 AM
Margin
₹332,806.25 approx for 100 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Dec 2 9:37 AM

Update
Trade Entered
Entry Price
₹3,287
N
Reputation: 8,253 • Dec 2 9:36 AM
Humus raises funds from Venture Catalysts, 9Unicorns & We Founders Circle
Humus aims to provide an end-to-end solution to simplify the complex logistics processes in the Indian agricultural sector.
The Economic Times
Like
Reply
S
Reputation: 5,741 • Dec 2 9:34 AM

Type
Sell
Instrument
SILVERM 26FEB21 FUT
Entry Price
₹64,070
Price@Trade
₹64,070
Target Price
₹63,001
Stop Price
₹64,261
Valid Till
Dec 2, 2020 11:20 AM
Margin
₹49,134.38 approx for 5 Qty
Status
Active
Like
Reply
C
Reputation: 86,917 • Dec 2 9:34 AM

Type
Sell
Instrument
ZINC 31DEC20 FUT
Entry Price
₹216.5
Price@Trade
₹216.5
Target Price
₹215
Stop Price
₹216.7
Valid Till
Dec 31, 2020 11:20 AM
Margin
₹2,470,625 approx for 100000 Qty
Status
Stoploss Hit
Exit Price
₹216.7
Net P&L
-₹20,000 (-0.81%)
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Dec 2 9:36 AM

Update
Stoploss Hit
Exit Price
₹216.7

#NIFTYBANK imp spot level for 03-dec are 29550, 29400
Like
Reply
C
Reputation: 86,917 • Dec 2 9:32 AM

Type
Sell
Instrument
ZINC 31DEC20 FUT
Entry Price
₹216.4  ₹216.5
Price@Trade
₹216.45
Target Price
₹215
Stop Price
₹216.6
Valid Till
Dec 31, 2020 11:20 AM
Margin
₹2,470,625 approx for 100000 Qty
Status
Exited before entry
Like
Reply (2)
See all replies
CRAZY WIZARD @CRAZYWIZARD
Dec 2 9:33 AM

Update
Entry Price Modified
Price @ Update
₹216.5
Original Entry Price
₹216.4
New Entry Price
₹216.5
CRAZY WIZARD @CRAZYWIZARD
Dec 2 9:33 AM

Update
Exited before entry
Price @ Update
₹216.5
H
Reputation: -429 • Dec 2 9:29 AM

Type
Buy
Instrument
NATURALGAS 25JAN21 FUT
Entry Price
₹213.2
Price@Trade
₹213.3
Target Price
₹220
Stop Price
₹211
Valid Till
Dec 2, 2020 11:20 AM
Margin
₹408,328.13 approx for 12500 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Dec 2 9:33 AM

Update
Trade Entered
Entry Price
₹213.2
S
Reputation: 5,741 • Dec 2 9:29 AM

Type
Sell
Instrument
GOLD 05FEB21 FUT
Entry Price
₹49,030
Price@Trade
₹49,030
Target Price
₹48,400
Stop Price
₹49,111
Valid Till
Dec 2, 2020 11:20 AM
Margin
₹449,821 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹49,111
Net P&L
-₹8,100 (-1.8%)
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Dec 2 9:33 AM

Update
Stoploss Hit
Exit Price
₹49,111

Type
Sell
Instrument
CRUDEOIL 18DEC20 FUT
Entry Price
₹3,291
Price@Trade
₹3,291
Target Price
₹3,275
Stop Price
₹3,307
Valid Till
Dec 2, 2020 11:20 AM
Margin
₹332,813 approx for 100 Qty
Status
Active
Like
Reply

#NIFTY50 imp spot level for 03-dec is 13070
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • AJANTPHARM - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization9,036.61
    Enterprise Value9,000.74
    Price to Earnings29.08
    Price to Book Value4.22
    Return on Capital Employed0.29
    Return on Equity0.22
    Face Value2
    Dividend YieldNA
  • AJANTPHARM - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    27-Feb-20Motilal OswalBuy1,655
    6-Feb-20Motilal OswalBuy1,435
    1-Aug-19ICICIdirect.comHold1,010
    2-Feb-19Reliance SecuritiesBuy1,225
    1-Feb-19ICICIdirect.comBuy1,100
    AJANTPHARM Brokerage Price Target
  • AJANTPHARM Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Dec 31550.515651546.651557.8
    Dec 215391552.61527.11545.1
    Dec 11545.61559.515301534.75
    Nov 27153015431516.051536.1
    Nov 2615261533.51510.11524
  • AJANTPHARM Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹1,549.25
    30 Day Moving Average₹1,565.33
    50 Day Moving Average₹1,570.74
    100 Day Moving Average₹1,555.82
    200 Day Moving Average₹1,476.14
  • AJANTPHARM - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue1,830.451,822.710
    Operating Profit546.81636.01-0.14
    Profit Before Tax562.44640.65-0.12
    Net Income427.52499.81-0.14
  • AJANTPHARM - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds2,1431,931.50.11
    Total Liabilities379381.35-0.01
    Total Assets2,5222,312.850.09
  • AJANTPHARM - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity219.16529.06-0.59
    Cash from Investing Activity-201.12-349.66-0.42
    Cash from Financing Activity-0.54-194.08-1
    Net Cash Flow17.5-14.68-2.19
  • AJANTPHARM - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.180.29
    Return on Equity0.220.33
    Return on Capital Employed0.290.43
  • AJANTPHARM - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.35
    3 Year CAGR Growth in Operating Profit0.17
    3 Year CAGR Growth in EBIDTA0.24
    3 Year CAGR Growth in Net Income0.4
    3 Yr CAGR Growth - Diluted EPS0.39
  • AJANTPHARM - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue1.18
    5 Year CAGR Growth in Operating Profit1.64
    5 Year CAGR Growth in EBIDTA1.89
    5 Year CAGR Growth in Net Income3.23
    3 Yr CAGR Growth - Diluted EPS0.12
  • AJANTPHARM - Recent News

    keyboard_arrow_down
    NewsBot
    Nov 20 7:48 AM
    Brokerages upgraded these 35 stocks in November; expect returns up to 40%
    Moneycontrol
    NewsBot
    Nov 19 1:03 AM
    Hot Stocks | Can bet on Ajanta Pharma, Bandhan Bank and REC for short term
    Moneycontrol
    NewsBot
    Nov 9 8:53 AM
    Buy Ajanta Pharma; target of Rs 1980: Anand Rathi
    Moneycontrol
    NewsBot
    Nov 7 12:33 PM
    Accumulate Ajanta Pharma; target of Rs 1771: Dolat Capital Market
    Moneycontrol
    NewsBot
    Nov 7 6:33 AM
    Buy Ajanta Pharmaceuticals; target of Rs 1960: ICICI Direct
    Moneycontrol
    NewsBot
    Nov 4 5:18 AM
    NewsBot
    Oct 29 3:33 AM
    Ajanta Pharma shares gain 4% on share buyback plans
    Moneycontrol
    NewsBot
    Oct 13 9:28 AM
    Covid medicines help Cipla, Glenmark post strong sales growth in a subdued pharma market
    Moneycontrol
    NewsBot
    Sep 29 3:26 AM
    Buy Ajanta Pharma, target price Rs 1695: ICICI Securities
    The Economic Times
    NewsBot
    Sep 28 5:36 AM
    Buy Ajanta Pharma, target price Rs 1815: Motilal Oswal
    The Economic Times
  • AJANTPHARM - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
  • AJANTPHARM - More Information

    keyboard_arrow_down

    Ajanta Pharma Limited:
    Ajanta Pharma Limited is among the nation’s most prestigious pharmaceutical company, announcing their mission to serve the global healthcare with empathy, innovation and technology. The firm was established in the year of 1973 with headquarter at Mumbai. The company is announcing to ‘Serve Healthcare Needs Worldwide’. The company is aiming to use cutting edge technology to bring innovations.
    The company is developing its business internationally to achieve their aim. The company is currently pursuing its business in India, USA and around thirty other countries in Asia, Africa, CIS and the Middle East. With a Research and Development team enriched with more than 750 scientists, Ajanta Pharma is possessing a workforce of more than 7,500 employees all over the world. The company has currently 1,400 products in different countries around the globe with a deep focus on the market of USA, expecting a good outcome. Ajanta Pharma has been manufacturing anti-malarial products for the health programmes in Africa approved by WHO.
    Company Information:
    Soon after its inception in 1973, Ajanta Pharma Limited has been pursuing tremendous achievements in its journey towards the golden jubilee. In 1979, the company produced branded ‘Over The Counter’ products along with developing its first manufacturing facility set-up at Chikalthana, India. By seven years the firm set up its second manufacturing facility at Paithan, India. By 1989, Ajanta Pharma reached a milestone of manufacturing more than 30 ‘Over The Counter’ products. The company intervened the international market for the first time in 1992. In 1995 the company developed its subsidiary at Mauritius with a manufacturing facility set-up. Millennium brought a credible achievement for the company while Ajanta Pharma had been enlisted in National Stock Exchange and Bombay Stock Exchange. The company intervened the domestic prescription market in 2002, introducing speciality segment force.
    As the company has been in the process of in traducing innovations, it developed its R&D facility at Kandivli. Establishing an Active Pharmaceutical Ingredient (API) Plant at Waluj in Aurangabad, the company got the approval of USFDA in 2007. In the same year, Ajanta Pharma developed a manufacturing facility in Aurangabad for rapid growth. The company received its international recognition in the same year by becoming the world’s first generic company to achieve WHO Geneva Pre-qualification for Anti-Malarial Drug. In 2010, Ajanta Pharma intervened the market of the Philippines through Ajanta Philippines Inc. Ophthalmology, Dermatology, Cardiology— these are the three segments where the company created its reign and emerged in the leading position in 2011.
    In the next year, the company achieved its place among the top ten pharmaceutical companies in Franco Africa. The company started its journey to explore the USA market in the year 2013. Ajanta Pharma inaugurated its Research & Development centre at Kandivli, Mumbai to expand its innovations and after that the business in a larger periphery. Inauguration of a new facility was done in Dahej, 2015 to fulfil the requirements of the USA market and WHO. Montelukas Sodium Oral Granules were announced to launch by Ajanta in 2015 along with the announcement of the launch of Montelukast IR Tablets and Montelukast Chewable Tablets in the US market. In the year 2017, the company developed its new facility in Guwahati. In the same year, USFDA has approved Ajanta Pharma’s Dahej facility.
    The company is currently spending 9% of its revenue in Research & Development in the financial year of 2019-20. From 28 different nationalities, the company has appointed more than 7500 people as its permanent staff. The total income in the fiscal year of 2019-20 is 2076 crore INR; the company has been enjoying a net profit of 387 crore INR in the same financial year. The current EBITDA margin of the company in the current fiscal year of 2019-20 is 28%.
    The company is announcing its philosophy as first to create opportunities and then optimize them on fullest.
    How Ajanta Pharma Ltd, is categorised as Pharmaceuticals and Health Care Sector, and Pharmaceuticals Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Ajanta Pharma Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Ajanta Pharma Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020